Complement in Candida albicans infections

Frontiers in Bioscience - Elite

Volumn 1 E, Issue 1, 2009, Pages 1-12

  Rambach, Gunter ^a   Speth, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antifungal complement functions; Candida albicans infections; Candidiasis; Complement evasion; Complement system; Innate immunity; Molecular mimicry; Review; Therapy

Indexed keywords

EID: 84883308599     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Mavor A. L., S. Thewes & B. Hube: Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets 6(8), 863-874 (2005)
2. Pappas P. G.: Invasive candidiasis. Infect Dis Clin North Am 20(3), 485-506 (2006)
3. Sobel J. D.: Vulvovaginal candidosis. Lancet 369(9577), 1961-1971 (2007)
4. Fidel P. L. Jr.: Immunity to Candida. Oral Dis 8(Suppl 2), 69-75 (2002)
5. Raska M., J. Bìláková, M. Krupka & E. Weigl: Candidiasis-do we need to fight or to tolerate the Candida fungus? Folia Microbiol (Praha) 52(3), 297-312 (2007)
6. Speth C., C. Lass-Flörl & Reinhard Würzner: Complement in fungal infections and complement evasion strategies. In: Immunology of fungal infections. Eds: Brown G. D., Netea M. G., Springer, Dordrecht, The Netherlands (2007)
7. Goldfarb R. D. & J. E. Parrillo: Complement. Crit Care Med 33(Suppl), 482-484 (2005)
8. Prodinger W. M., R. Würzner, H. Stoiber & M. P. Dierich: Complement. In: Fundamental Immunology. Ed: Paul W. E., Lippincott, Philadelphia (2003)
9. Hugli T. E.: Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol 153, 181-208 (1990)
10. Guo R. F. & P. A. Ward: Role of C5a in inflammatory responses. Annu Rev Immunol 23(1), 821-852 (2005)
11. Müller-Eberhard H. J.: The membrane attack complex of complement. Annu Rev Immunol 4, 503-528 (1986)
12. Petersen S. V., S. Thiel, L. Jensen, T. Vorup-Jensen, C. Koch & J. C. Jensenius: Control of the classical and the MBL pathway of complement activation. Mol Immunol 37(18), 803-811 (2000)
13. Krych-Goldberg M. & J. P. Atkinson: Structurefunction relationships of complement receptor type 1. Immunol Rev 180(1), 112-122 (2001)
14. Fearon D. T. & M. C. Carroll: Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18, 393-422 (2000)
15. Chen Z., S. B. Koralov & G. Kelsoe: Regulation of the humoral immune responses by CD21/CD35. Immunol Rev 176, 194-204 (2000)
16. Ehlers M. R.: CR3: a general purpose adhesionrecognition receptor essential for innate immunity. Microbes Infect 2(3), 289-294 (2000)
17. Helmy K. Y., K. J. Katschke, N. N. Gorgani, N. M. Kljavin, J. M. Elliott, L. Diehl, S. J. Scales, N. Ghilardi & M. van Lookeren Campagne: CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124(5), 915-927 (2006)
18. Vogt L., N. Schmitz, M. O. Kurrer, M. Bauer, H. I. Hinton, S. Behnke, D. Gatto, P. Sebbel, R. R. Beerli, I. Sonderegger, M. Kopf, P. Saudan & M. F. Bachmann: VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 116(10), 2817-2826 (2006)
19. Wiesmann C., K. J. Katschke, J. Yin, K. Y. Helmy, M. Steffek, W. J. Fairbrother, S. A. McCallum, L. Embuscado, L. De Forge, P. E. Hass & & M. van Lookeren Campagne: Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444(7116), 217-220 (2006)
20. Katschke K. J. Jr., K. Y. Helmy, M. Steffek, H. Xi, J. Yin, W. P. Lee, P. Gribling, K. H. Barck, R. A. Carano, R. E. Taylor, L. Rangell, L. Diehl, P. E. Hass, C. Wiesmann & M. van Lookeren Campagne: A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med 204(6), 1319-1325 (2007)
21. Gerard N. P. & C. Gerard: The chemotactic receptor for human C5a anaphylatoxin. Nature 349(6310), 614-617 (1991)
22. Gerard N. P., B. Lu, P. Liu, S. Craig, Y. Fujiwara, S. Okinaga & C. Gerard: An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 280(48), 39677-39680 (2005)
23. Eggleton P., K. B. Reid & A. J. Tenner: C1q-how many functions? How many receptors? Trends Cell Biol 8(11), 428-431 (1998)
24. Liu F., Q. Liao & Z. Liu: Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 92(1), 43-47 (2006)
25. Lukasser-Vogl E., A. Gruber, C. Lass-Flörl, A. Eder, A. K. Høgåsen, B. P. Morgan, M. P. Dierich & R. Würzner: Membrane attack complex formation on yeast as trigger of selective release of terminal complement proteins from human polymorphonuclear leukocytes. FEMS Immunol Med Microbiol 28(1), 15-23 (2000)
26. Babula O., G. Lazdane, J. Kroica, W. J. Ledger & S. S. Witkin: Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in latvian women. Clin Infect Dis 37(5), 733-737 (2003)
27. Giraldo P. C., O. Babula, A. K. Goncalves, I. M. Linhares, R. L. Amaral, W. J. Ledger & S. S. Witkin: Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 109(5), 1123-1128 (2007)
28. Gelfand J. A., D. L. Hurley, A. S. Fauci & M. M. Frank: Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis 138(1), 9-16 (1978)
29. Ray T. L. & K. D. Wuepper: Experimental cutaneous candidiasis in rodents; II. Role of the stratum corneum barrier and serum complement as a mediator of a protective inflammatory response. Arch Dermatol 114(4), 539-543 (1978)
30. Naked G. M., M. P. C. Florido, P. Ferreira de Paula, A. M. Vinet, J. S. Inostroza & L. Isaac: Deficiency of human complement factor I associated with lowered factor H. Clin Immunol 96(2), 162-167 (2000)
31. Kozel T. R., L. C. Weinhold & D. M. Lupan: Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect Immun 64(8), 3360-3368 (1996)
32. Sohnle P. G., M. M. Frank & C. H. Kirkpatrick: Deposition of complement components in the cutaneous lesions of chronic mucocutaneous candidiasis. Clin Immunol Immunopathol 5(3), 340-350 (1976)
33. Sohnle P. G. & C. H. Kirkpatrick: Deposition of complement in the lesions of experimental cutaneous candidiasis in guinea pigs. J Cutan Pathol 3(5), 232-238 (1976)
34. Guhad F. A., H. E. Jensen & J. Hau: Complement activation in SCID and nude mice is related to severity of tissue inflammation in the Candida mastitis model. FEMS Microbiol Lett 192(1), 27-31 (2000)
35. Zhang M. X. & T. R. Kozel: Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect Immun 66(10), 4845-4850 (1998)
36. Zhang M. X., J. E. Cutler, Y. Han & T. R. Kozel: Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect Immun 66(12), 6027-6029 (1998)
37. Han Y., T. R. Kozel, M. X. Zhang, R. S. McGill, M. C. Carroll & J. E. Cutler: Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 167(3), 1550-1557 (2001)
38. Cutler J. E.: Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5(4), 383-392 (2005)
39. Xin H. & J. E. Cutler: Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect Immun 74(7), 4310-4321 (2006)
40. Kozel T. R., R. S. McGill, A. Percival & Q. Zhou: Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 72(1), 209-218 (2004)
41. Lillegard J. B., R. B. Sim, P. Thorkildson, M. A. Gates & T. R. Kozel: Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 193(11), 1589-1597 (2006)
42. Ip W. K. & Y. L. Lau: Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 190(3), 632-640 (2004)
43. Pellis V., F. De Seta, S. Crovella, F. Bossi, R. Bulla, S. Guaschino, O. Radillo, P. Garred & F. Tedesco: Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin Exp Immunol 139(1), 120-126 (2005)
44. Zhang M. X., D. M. Lupan & T. R. Kozel: Mannanspecific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun 65(9), 3822-3827 (1997)
45. Kozel T. R.: Activation of the complement system by pathogenic fungi. Clin Microbiol. Rev. 9(1), 34-46 (1996)
46. Gruber A., E. Lukasser-Vogl, M. Borg-von Zepelin, M. P. Dierich & R. Würzner: Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 177(4), 1057-1063 (1998)
47. Zhang M. X., M. C. Bohlmann, C. Itatani, D. R. Burton, P. W. H. I. Parren, S. C. St. Jeor & T. R. Kozel: Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74(1), 362-369 (2006)
48. Pereira H. A. & C. S. Hosking: The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin Exp Immunol 57(2), 307-14 (1984)
49. Szabo I., L. Guan & T. J. Rogers: Modulation of macrophage phagocytic activity by cell wall components of Candida albicans. Cell Immunol 164(2), 182-188 (1995)
50. Andrews T. & K. E. Sullivan: Infections in patients with inherited defects in phagocytic function. Clin Microbiol Rev 16(4), 597-621 (2003)
51. Forsyth C. B. & H. L. Mathews: Lymphocytes utilize CD11b/CD18 for adhesion to Candida albicans. Cell Immunol 170(1), 91-100 (1996)
52. Forsyth C. B., E. F. Plow & L. Zhang: Interaction of the fungal pathogen Candida albicans with integrin CD11b/CD18: recognition by the I domain is modulated by the lectin-like domain and the CD18 subunit. J Immunol 161(11), 6198-6205 (1998)
53. Lavigne L. M., J. E. Albina & J. S. Reichner: Betaglucan is a fungal determinant for adhesion-dependent human neutrophil functions. J Immunol 177(12), 8667-8675 (2006)
54. Forsyth C. B. & H. L. Mathews: Lymphocyte adhesion to Candida albicans. Infect Immun 70(2), 517-527 (2002)
55. Romani L., C. Montagnoli, S. Bozza, K. Perrucione, A. Spreca, P. Allavena, S. Verbeek, R. A. Calderone, F. Bistoni & P. Puccetti: The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int Immunol 16(1), 149-161 (2004)
56. Triebel T., B. Grillhösl, L. Kacani, C. P. Lell, A. Fuchs, C. Speth, C. Lass-Flörl, J. Steinmann, M. P. Dierich & R. Würzner: Importance of the terminal complement components for immune defence against Candida. Int J Med Microbiol 37(5), 527-536 (2003)
57. Ghezzi M. C., G. Raponi, S. Angeletti & C. Mancini: Serum-mediated enhancement of TNF-alpha release by human monocytes stimulated with the yeast form of Candida albicans. J Infect Dis 178(6), 1743-1749 (1998)
58. Sonesson A., L. Ringstad, E. A. Nordahl, M. Malmsten, M. Mörgelin & A. Schmidtchen: Antifungal activity of C3a and C3a-derived peptides against Candida. Biochim Biophys Acta 1768(2), 346-358, (2007)
59. Mullick A., M. Elias, S. Picard, L. Bourget, O. Jovcevski, S. Gauthier, A. Tuite, P. Harakidas, C. Bihun, B. Massie & P. Gros: Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun 72(10), 5868-5876 (2004)
60. Tuite A., M. Elias, S. Picard, A. Mullick & P. Gros: Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/6J mice. Genes Immun 6(8), 672-682 (2005)
61. Mullick A., Z. Leon, G. Min-Oo, J. Berghout, R. Lo, E. Daniels & P. Gros: Cardiac failure in C5-deficient A/J mice after Candida albicans infection. Infect Immun 74(8), 4439-4451 (2006)
62. Würzner R.: Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 36(4-5), 249-260 (1999)
63. Monod M., S. Capoccia, B. Lechenne, C. Zaugg, M. Holdom & O. Jousson: Secreted proteases from pathogenic fungi. Int J Med Microbiol 292(5-6), 405-419 (2002)
64. Kaminishi H., H. Miyaguchi, T. Tamaki, N. Suenaga, M. Hisamatsu, I. Mihashi, H. Matsumoto, H. Maeda & Y. Hagihara: Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 63(3), 984-988 (1995)
65. Naglik J. R., S. J. Challacombe & B. Hube: Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67(3), 400-428 (2003)
66. Lian C. H. & W. D. Liu: Diffearential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 50(5), 383-390 (2007)
67. Blom A. M.: Strategies developed by bacteria and virus for protection from the human complement system. Scand J Clin Lab Invest 64(5), 479-496 (2004)
68. Kirkitadze M. D. & P. N. Barlow: Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180, 146-161 (2001)
69. Zipfel P. F., R. Würzner & C. Skerka: Complement evasion of pathogens: Common strategies are shared by diverse organisms. Mol Immunol 44(16), 3850-3857 (2007)
70. Di Scipio R. G., P. J. Daffern, I. U. Schraufstätter & P. Sriramarao: Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol 160(8), 4057-4066 (1998)
71. Meri T., A. Hartmann, D. Lenk, R. Eck, R. Würzner, J. Hellwage, S. Meri & P. F. Zipfel: The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 70(9), 5185-51192 (2002)
72. Blom A. M., B. O. Villoutreix & B. Dahlbäck: Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 40(18), 1333-1346 (2004)
73. Meri T., A. M. Blom, A. Hartmann, D. Lenk, S. Meri & P. F. Zipfel: The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun 72(11), 6633-6641 (2004)
74. Brodeur S. R., F. Angelini, L. B. Bacharier, A. M. Blom, E. Mizoguchi, H. Fujiwara, A. Plebani, L. D. Notarangelo, B. Dahlback, E. Tsitsikov & R. S. Geha: C4bbinding protein (C4BP) activates B cells through the CD40 receptor. Immunity 18(6), 837-848 (2003)
75. Gilmore B. J., E. M. Retsinas, J. S. Lorenz & M. K. Hostetter: An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J Infect Dis 157(1), 38-46 (1988)
76. Eigentler A., T. F. Schulz, C. Larcher, E. M. Breitwieser, B. L. Myones, A. L. Petzer & M. P. Dierich: C3bi-binding protein on Candida albicans: temperaturedependent expression and relationship to human complement receptor type 3. Infect Immun 57(2), 616-622 (1989)
77. Hostetter M. K., J. S. Lorenz, L. Preus & K. E. Kendrick: The iC3b receptor on Candida albicans: subcellular localization and modulation of receptor expression by glucose. J Infect Dis 161(4), 761-768 (1990)
78. Gustafson K. S., G. M. Vercellotti, C. M. Bendel & M. K. Hostetter: Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest 87(6), 1896-1902 (1991)
79. Bendel C. M. & M. K. Hostetter: Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides. J Clin Invest 92(4), 1840-1809 (1993)
80. Ollert M. W., E. Wadsworth & R. A. Calderone: Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans. Infect Immun 58(4), 909-913 (1990)
81. Gale C., D. Finkel, N. Tao, M. Meinke, M. McClellan, J. Olson, K. Kendrick & M. Hostetter: Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. Proc Natl Acad Sci USA 93(1), 357-361 (1996)
82. Gale C. A., C. M. Bendel, M. McClellan, M. Hauser, J. M. Becker, J. Berman & M. K. Hostetter: Linkage of Adhesion, Filamentous Growth, and Virulence in Candida albicans to a Single Gene, INT1. Science 279(5355), 1355-1358 (1998)
83. Moors M. A., T. L. Stull, K. J. Blank, H. R. Buckley & D. M. Mosser: A role for complement receptor-like molecules in iron acquisition by Candida albicans. J Exp Med 175(6), 1643-1651 (1992)
84. Heidenreich F. & M. P. Dierich: Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun 50(2), 598-600 (1985)
85. Linehan L., E. Wadsworth & R. Calderone: Candida albicans C3d receptor, isolated by using a monoclonal antibody. Infect Immun 56(8), 1981-1986 (1988)
86. Saxena A. & R. Calderone: Purification and characterization of the extracellular C3d-binding protein of Candida albicans. Infect Immun 58(2), 309-314 (1990)
87. Edwards J. E. Jr., T. A. Gaither, J. J. O'Shea, D. Rotrosen, T. J. Lawley, S. A. Wright, M. M. Frank & I. Green: Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol 137(11), 3577-3583 (1986)
88. Franzke S., R. A. Calderone & K. Schaller: Isolation of avirulent clones of Candida albicans with reduced ability to recognize the CR2 ligand C3d. Infect Immun 61(6), 2662-2669 (1993)
89. Kanbe T., R. K. Li, E. Wadsworth, R. A. Calderone & J. E. Cutler: Evidence for expression of the C3d receptor of Candida albicans in vitro and in vivo obtained by immunofluorescence and immunoelectron microscopy. Infect Immun 59(5), 1832-1838 (1991)
90. Fukayama M., E. Wadsworth & R. Calderone: Expression of the C3d-binding protein (CR2) from Candida albicans during experimental candidiasis as measured by lymphoblastogenesis. Infect Immun 60(1), 8-12 (1992)
91. Tronchin G., J. P. Bouchara & R. Robert: Dynamic changes of the cell wall surface of Candida albicans associated with germination and adherence. Eur J Cell Biol 50(2), 285-290 (1989)
92. Valdimarsson H., T. Vikingsdottir, P. Bang, S. Saevarsdottir, J. E. Gudjonsson, O. Oskarsson, M. Christiansen, L. Blou, I. Laursen & C. Koch: Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol 59(1), 97-102 (2004)